Top Markets
#1 MarsCoin MarsCoin +48.28%
#2 Palladium Network Palladium Network +27.97%
#3 Siren Siren +27.75%
#4 Status Status +21.38%
#5 Useless Coin Useless Coin +16.56%
#6 BankrCoin BankrCoin +15.25%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +15.16%
#8 Bedrock Bedrock +14.18%
#9 Ankr Network Ankr Network +12.74%
#10 Arweave Arweave +12.66%
Coin of the day
MarsCoin MarsCoin
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
KemPharm, Inc. KemPharm, Inc.

KemPharm, Inc.

KMPH
Classifica tra le azioni #18404
KemPharm, Inc. operates as a specialized pharmaceutical firm focused on... KemPharm, Inc. operates as a specialized pharmaceutical firm focused on discovering and advancing proprietary prodrugs to tackle serious medical conditions across the United States. The company employs its innovative Ligand Activated Therapy (LAT) platform to create improved prodrug versions of medications already approved by the FDA, and also to develop prodrugs from existing compounds for potential applications in new disease indications. Its pipeline of investigational prodrugs strategically targets high-need areas such as attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) disorders, including idiopathic hypersomnia (IH). KP1077, KemPharm's leading experimental compound, is a prodrug of d-methylphenidate, known as serdexmethylphnidate, and is currently in Phase II clinical trials for the treatment of IH and narcolepsy. Additionally, the company is advancing KP879, a prodrug candidate designed to treat stimulant use disorder, which is undergoing Phase I clinical evaluation. KemPharm has also obtained FDA approval for AZSTARYS, a new once-daily ADHD treatment for patients aged six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company holds collaboration and license agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Founded in 2006, KemPharm, Inc. is headquartered in Celebration, Florida.
Prezzo delle azioni
$5.81
Ultima sincronizzazione: 2023-02-28
Capitalizzazione di mercato
$200.14M
Variazione (1 giorno)
-0.34%
Variazione (1 anno)
0.00%
Paese
US
Scambia KemPharm, Inc. (KMPH)

Categoria

Healthcare
Il prezzo KMPH con la capitalizzazione del mercato della B
KemPharm, Inc. KemPharm, Inc.
KMPH
$5.81
Capitalizzazione di mercato di KemPharm, Inc.(KMPH)
Capitalizzazione di mercato: $200.14M
A partire dal September 2026, KemPharm, Inc. ha una capitalizzazione di mercato pari a $200.14M. Questo rende KemPharm, Inc. la 18404th azienda più preziosa al mondo per capitalizzazione di mercato secondo i nostri dati. La capitalizzazione di mercato è il valore totale delle azioni in circolazione di una società quotata e viene comunemente utilizzata per misurarne il valore.
Storia della capitalizzazione di mercato di KemPharm, Inc. dal 2015 al 2026
KMPH in paragone con la classifica dei più popolari stocks
Il prezzo per KMPH Attivo B Capitalizzazione del mercato a B Risultati
KemPharm, Inc. KemPharm, Inc.
$157,467 $200.14M
NVIDIA Corporation NVIDIA Corporation
NVDA
$5.424T +2,710,172.77%
KemPharm, Inc. KemPharm, Inc.
$138,644 $200.14M
Apple Inc. Apple Inc.
AAPL
$4.776T +2,386,194.05%
KemPharm, Inc. KemPharm, Inc.
$117,624 $200.14M
Alphabet Inc. Alphabet Inc.
GOOG
$4.052T +2,024,407.26%
KemPharm, Inc. KemPharm, Inc.
$107,151 $200.14M
Microsoft Corporation Microsoft Corporation
MSFT
$3.691T +1,844,144.48%
KemPharm, Inc. KemPharm, Inc.
$79,665.21 $200.14M
Amazon.com, Inc. Amazon.com, Inc.
AMZN
$2.744T +1,371,073.95%